Formulated for prostate cancer to manage androgen binding and support tumor growth inhibition.
Mechanism of Action
Bicalutamide competitively inhibits androgen binding at its receptor in the prostate. By blocking the action of testosterone, it effectively prevents the growth and proliferation of hormone-sensitive malignant cells.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
6 days (half-life)
Contraindications
Pregnancy, Hypersensitivity to bicalutamide, Use in females
Information related to Bicalutamide is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
